Indefinite Delivery Contract SPE2DB25D9303

Award Date 9/5/24
Last Date to Order 11/30/26
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, is valid through November 2026 and enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The IDC covers an extensive portfolio of...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including...
The Indefinite Delivery Contract (IDC) SPE2DX15D9642 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The single-award IDC, valued up to $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The IDC covers an extensive portfolio of...
This indefinite delivery contract (IDC) with the Defense Logistics Agency (DLA) was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The single-award IDC, valued up to $499,999,999, covers the period from October 10, 2024 through December 31, 2025. Under this IDC, DMS Pharmaceutical Group will provide a comprehensive range of pharmaceutical products to fulfill the recurring medical supply needs of military health facilities...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The single-award IDC, valued at $499,999,999 and valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 single-award IDC, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The IDC covers an extensive portfolio of...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, covers the delivery of a comprehensive range of pharmaceutical products to support the recurring medical supply needs of military healthcare facilities worldwide. The contract enables the DLA to issue firm fixed-price delivery orders for branded and generic prescription...
This single-award Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide. The IDC covers a comprehensive portfolio of...
  • SPE2DB25D9303
    Indefinite Delivery Contract
  • 15
    Federal Contract Awards

This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The single-award IDC, valued up to $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to fulfill the recurring medical supply needs of military health facilities worldwide under the SPE2DB program.

The IDC covers a vast array of pharmaceutical items, from common medications like antibiotics and cardiovascular drugs to specialized products such as oncology drugs, biologics, and medical consumables. This contract allows DMS Pharmaceutical Group to serve as a crucial supplier in the federal pharmaceutical supply chain, providing both routine and critical medications to support the diverse medical requirements of military personnel and their dependents across various Department of Defense healthcare facilities. The contract has an ultimate completion date of November 30, 2026.

Generated 1/1/25, 9:05 AM